Friday, July 4, 2025 7/4/2025

Novel sequencing by synthesis platform to greatly reduce the cost of nucleic acid sequencing

Award Number: R44HG010558
ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/22/2019
PERIOD OF PERFORMANCE END DATE: 09/17/2020

Group Awards By:

View Award Description

Novel sequencing by synthesis platform to greatly reduce the cost of nucleic acid sequencing - PROJECT SUMMARY Ultima Genomics, Inc. proposes to develop a novel high-throughput sequencing technology platform that will reduce cost ($/Gbase) substantially compared with state-of-the-art commercial technologies. The new technol- ogy to be developed in the SBIR project will particularly benefit DNA sequencing applications that are cost constrained, such as sequencing large populations, generating methylation and transcriptome profiles for millions of single cells, and enabling liquid biopsy applications. Target customers include genome centers, CROs, research labs, and clinical labs. The company is pioneering a series of inter-related innovations that mutually reinforce one another in a virtu- ous circle to achieve much lower cost. In Phase 1 of the FastTrack project, the company will integrate these separate innovations into an alpha prototype and prove the feasibility of the platform by performing shotgun sequencing of human genome reference samples. In Phase 2, the company will further develop the core plat- form technology; build a beta instrument that achieves highly competitive specifications for accuracy, read length, throughput, time to answer, and cost; and validate performance rigorously using multiple reference samples. By dramatically reducing sequencing cost, Ultima Genomics' technology will directly impact a wide range of scientific capabilities with direct relevance for public health, including characterization of tumors, detection of early stage cancers through blood test, and personalized/precision medicine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	ULTIMA GENOMICS, INC.	7979 GATEWAY BLVD STE 101	NEWARK	CA	94560	ALAMEDA	USA	Human Genome Research	000	2	11/12/2020	EXTENSION WITH OR WITHOUT FUNDS	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	ULTIMA GENOMICS, INC.	7979 GATEWAY BLVD STE 101	NEWARK	CA	94560	ALAMEDA	USA	Human Genome Research	000	1	9/14/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $2,224,579 )
2019	2019	ULTIMA GENOMICS, INC.	7979 GATEWAY BLVD STE 101	NEWARK	CA	94560	ALAMEDA	USA	Human Genome Research	000	1	5/22/2019	NEW	$299,441
2019	2019	ULTIMA GENOMICS, INC.	7979 GATEWAY BLVD STE 101	NEWARK	CA	94560	ALAMEDA	USA	Human Genome Research	001	1	9/17/2019	NEW	$0
2019	2019	ULTIMA GENOMICS, INC.	7979 GATEWAY BLVD STE 101	NEWARK	CA	94560	ALAMEDA	USA	Human Genome Research	002	2	9/18/2019	EXTENSION WITH OR WITHOUT FUNDS	$1,925,138
														Subtotal = $2,224,579

Grand Total All Awards = $2,224,579

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel sequencing by synthesis platform to greatly reduce the cost of nucleic acid sequencing

Award Number: R44HG010558

ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/22/2019

PERIOD OF PERFORMANCE END DATE: 09/17/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer